SCHEMBL4080463

SCHEMBL4080463

COc1ccc(S(=O)(=O)N(CCCN(C)c2ccccc2)Cc2cc3cccc(C)c3[nH]c2=O)cc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.58
ALDH1A1 P00352 8/20 0.58
HPGD P15428 5/20 0.58
PLEC Q15149 1/20 0.52
HSD17B10 Q99714 6/20 0.51
MAPK1 P28482 3/20 0.51
POLB P06746 1/20 0.51
KMT2A Q03164 2/20 0.51
MAPT P10636 1/20 0.51
THRB P10828 1/20 0.51
APOBEC3A P31941 1/20 0.50
APOBEC3G Q9HC16 1/20 0.50
USP2 O75604 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
MEN1 O00255 1/20 0.49
GAA P10253 1/20 0.49
LMNA P02545 1/20 0.49
ATM Q13315 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4071631 0.88 KDM4E (0.70) KDM4EALDH1A1HPGDPLECHSD17B10
SCHEMBL4074094 0.88 KDM4E (0.61) KDM4EALDH1A1HPGDPLECHSD17B10
SCHEMBL4081531 0.87 KDM4E (0.59) KDM4EALDH1A1HPGDPLECHSD17B10
SCHEMBL4074624 0.87 KDM4E (0.60) KDM4EALDH1A1HPGDPLECHSD17B10
SCHEMBL4077449 0.83 KDM4E (0.62) KDM4EALDH1A1HPGDHSD17B10KMT2A
SCHEMBL4072759 0.82 ALDH1A1 (0.60) KDM4EALDH1A1HPGDPLECHSD17B10
SCHEMBL4070694 0.81 KDM4E (0.64) KDM4EALDH1A1HPGDHSD17B10MAPK1
SCHEMBL4081567 0.80 ALDH1A1 (0.67) KDM4EALDH1A1HPGDPLECHSD17B10
SCHEMBL4078823 0.80 HSD17B10 (0.80) KDM4EALDH1A1HPGDPLECHSD17B10
SCHEMBL4078112 0.80 KDM4E (0.58) KDM4EALDH1A1HPGDPLECHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP claimed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US claimed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO claimed
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP disclosed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US disclosed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof ABCG2, ATP5ME, ATP5MG KDM4E 2403/4885ALDH1A1 1055/4885HPGD 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.